Fab2
Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.
$500MSeries A
ParticipantDF
Duquesne Family Office
Activity from announced rounds
Activity in this selectionUnited States · Oct 19, 2026 · Jul 22, 2026
Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.
Recorded funding activity
Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $660M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedRatio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosed